Meeting
2023 ASCO Annual Meeting
Selection biases in the systematic collection of breast biobank specimens.
Authors
Yael Bar
Massachusetts General Hospital, Boston, MA
Yael Bar , Gary X. Wang , Gabrielle E. Gioia , Veerle I. Bossuyt , Shirley Shinn-Huey Chou , Steven J. Isakoff , Beverly Moy , Leif W. Ellisen , Constance Dobbins Lehman , Laura Spring
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Health Services Research and Quality Improvement
Track
Quality Care/Health Services Research
Sub Track
Access to Care
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 6533)
DOI
10.1200/JCO.2023.41.16_suppl.6533
Abstract #
6533
Poster Bd #
25
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
A randomized, phase II study of repeated rhenium-188-HEDP (rhenium) combined with docetaxel versus docetaxel alone in castration resistant prostate cancer (CRPC) metastatic to bone: The Taxium II trial.
First Author: Joyce M. van Dodewaard-de Jong
Poster
2011 Genitourinary Cancers Symposium
Phase II study of maintenance therapy with temsirolimus (TEM) after response to first-line docetaxel (TAX) chemotherapy in castration-resistant prostate cancer (CRPC).
First Author: Urban Emmenegger
Poster
2021 ASCO Annual Meeting
A randomized phase II trial of second-line treatment for advanced soft tissue sarcoma comparing trabectedin, eribulin and pazopanib (2ND-STEP, JCOG1802).
First Author: Makoto Endo
Poster
2019 ASCO Annual Meeting
A multicentric phase II randomized trial of docetaxel (D) plus enzalutamide (E) versus docetaxel (D) as first-line chemotherapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): CHEIRON study.
First Author: Orazio Caffo